Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Documentation of patient history & essential key signs, within the Clinical Information Network (CIN), improved to over 90 percent across 14 hospitals. Reports generated indicate a steady improvement in data collection.

CTMGH logo for News

While the data has been useful and leading to improved quality of care and decisions in the hospitals, it has also contributed to increased knowledge on; monitoring of vital signs in children admitted to hospitals, variation in and risk factors for paediatric inpatient all-cause mortality in a low income setting, improving documentation of clinical care and more, as highlighted in the CIN timeline. 

Speaking at the meeting on 24th April, Prof Grace Irimu and Prof Mike English noted that the success of CIN has largely been driven by hospital teams led by paediatricians who collect data on common childhood illnesses and diseases that lead to child deaths.

The Ministry of Health, the Kenya Paediatric Association and KEMRI-Wellcome Trust seek to get more counties on board in 2017, with an aim of improving data collection leading to quality care and more opportunities to broaden knowledge based on evidence from this data. Hospitals currently in the network are: Machakos, Embu, Kiambu, Kerugoya, Mbagathi, Nyeri, Busia, Kisumu East, Mama Lucy, Kakamega, Mbale, Karatina, Vihiga and Kitale.

Similar stories

RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19

@Oxford Research

Convalescent plasma has been widely used as a treatment for COVID-19 but to date there has been no convincing evidence of the effect of convalescent plasma on clinical outcomes in patients admitted to hospital with COVID-19. Recruitment to the convalescent plasma arm of the RECOVERY trial has now closed. The preliminary analysis based on 1873 reported deaths among 10,406 randomised patients shows no significant difference in the primary endpoint of 28-day mortality. Recruitment to all other treatment arms – tocilizumab, aspirin, colchicine, and Regeneron’s antibody cocktail – continues as planned.

Check-list recommended to improve reporting of microscopy methods and results in malaria studies

@Oxford MORU Publication Research

A study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.

Receiving and responding to community feedback during health system crises in Kenya

KWTRP Publication Research

The responsiveness of a health system is one of its goals, alongside fairness in financing and outcomes. Listening and responding to the public can make a health system stronger and fairer. However, responsiveness is likely to be undermined, especially for vulnerable and marginal populations, in periods of crises such as disease outbreaks. In the current COVID-19 crisis, there has been more focus on health system control interventions, with minimal consideration of community views. KWTRP colleagues in Kenya consider community engagement and citizens feedback channels, concerns raised by the public and how they were handled, and highlight lessons learned.

RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19

@Oxford Research

Established in March 2020, the RECOVERY trial tests a range of potential treatments for COVID-19, including azithromycin, a widely used antibiotic that also reduces inflammation. The azithromycin arm of the trial was established to determine whether or not the drug has a meaningful benefit among patients hospitalised with COVID-19. A preliminary analysis shows no significant difference in the primary endpoint of 28-day mortality; there was also no evidence of beneficial effects on the risk of progression to mechanical ventilation or length of hospital stay.

Knowledge brokering platform launched to support health systems in the African region

KWTRP

The World Health Organization and partners including the KEMRI Wellcome Trust Research Programme launched AHOP (African Health Observatory Platform), an online platform to promote the exchange of evidence and experience across countries in the African region. By working to foster evidence-informed decision-making in an endeavor to re-engineer health service delivery, the initiative is expected to drive countries’ health system resilience efforts.

New study on the risk of Plasmodium vivax parasitaemia after Plasmodium falciparum malaria

@Oxford MORU Publication Research

A new study quantifying the high risk of Plasmodium vivax parasitaemia after treatment of Plasmodium falciparum malaria aims to identify populations in which a policy of universal radical cure, combining artemisinin-based combination therapy with a hypnozoitocidal antimalarial drug, would be most beneficial.